| Patricia O'brien, RN | |
|
501 Park Hill Dr, Fredericksburg, VA 22401-3377 | |
| (540) 372-6737 | |
| (540) 372-2076 |
| Full Name | Patricia O'brien |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist |
| Location | 501 Park Hill Dr, Fredericksburg, Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194197616 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364S00000X | Clinical Nurse Specialist | 0001082742 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Patricia O'brien, RN 501 Park Hill Dr, Fredericksburg, VA 22401-3377 Ph: (540) 372-6737 | Patricia O'brien, RN 501 Park Hill Dr, Fredericksburg, VA 22401-3377 Ph: (540) 372-6737 |
News Archive
Volcano Corporation, a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today said revenues in the fourth quarter of 2011 increased 14 percent versus the fourth quarter of 2010.
A study aimed at better understanding why some critically ill patients develop multidrug-resistant infections is underway by researchers at The University of Texas Health Science Center at Houston.
Recent news coverage has consumers concerned about the alarming amount of contaminants, such as pesticides and heavy metals, being found in herbal supplements. NSF International, an independent, not-for-profit public health organization, helps ease these concerns by testing and certifying supplements to ensure they are free of undeclared substances and unacceptable contaminants.
Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy.
› Verified 8 days ago
Rebecca Bulman, Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 4510 Plank Rd, Ste 200, Fredericksburg, VA 22407 Phone: 540-785-9900 Fax: 540-785-9960 | |
Mrs. Laura Larson, CPNP Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 331 Park Hill Dr, Fredericksburg, VA 22401 Phone: 540-368-8091 |